Erdafitinib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Erdafitinib: From Urothelial Carcinoma to Pulmonary Hypertension
One-Sentence Summary
Erdafitinib is a pan-FGFR1-4 tyrosine kinase inhibitor internationally approved for FGFR-altered urothelial carcinoma (this drug is not currently marketed in Taiwan, so this original-indication context comes from general drug knowledge, not from the Taiwan regulatory dataset in this evidence pack). The TxGNN model predicts it may be effective for Pulmonary Hypertension, with a prediction score of 99.38%, but currently no clinical trials and no literature support this specific prediction — it is a pure AI/knowledge-graph inference.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Urothelial carcinoma, FGFR3/2-altered (international label; not covered by Taiwan regulatory data in this pack) |
| Predicted New Indication | Pulmonary Hypertension |
| TxGNN Prediction Score | 99.38% |
| Evidence Level | L5 |
| Taiwan Market Status | ✗ Not marketed (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for erdafitinib is not available in this evidence pack (flagged as a data gap, DG002 – High severity). Based on the knowledge-graph rationale attached to this candidate, erdafitinib is understood to be a pan-FGFR1-4 tyrosine kinase inhibitor, and this is partially corroborated by the one literature record retrieved for this drug (Roskoski 2020, PMID 31862477), which classifies it among small-molecule protein kinase inhibitors approved by the FDA in 2019.
The proposed link to pulmonary hypertension rests on the general biology of FGF/FGFR signaling in pulmonary vascular smooth muscle cell proliferation and vascular remodeling — a pathway implicated in pulmonary arterial hypertension pathophysiology, with some exploratory animal-model work on FGFR inhibition reversing vascular remodeling.
However, this connection is indirect and inferential. There is no clinical trial, no case report, and no mechanistic study directly linking erdafitinib to pulmonary hypertension in the evidence collected. The prediction should be treated as a knowledge-graph-generated hypothesis rather than an evidence-backed candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Erdafitinib is not marketed in Taiwan — 0 authorizations on record, no license entries available.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (pan-FGFR1-4 small-molecule tyrosine kinase inhibitor, per Roskoski 2020 review of FDA-approved kinase inhibitors) |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (pulmonary hypertension) has no clinical trial or literature support — only an inferential knowledge-graph mechanistic link — placing it at evidence level L5. This is compounded by a Blocking data gap on TFDA label warnings/contraindications (DG001), which alone prevents any S1 safety pre-screening, and a High-severity gap on confirmed MOA (DG002).
Across all 10 predicted indications for this candidate, only rheumatoid arthritis (rank 4) has any literature hit, and that single reference (PMID 31862477) is a general kinase-inhibitor review with no RA-specific data, giving it evidence level L4 — still not sufficient for progression. No other candidate has any clinical or literature evidence.
To proceed, the following is needed:
- TFDA label/PDF (warnings, contraindications) to clear the Blocking data gap (DG001)
- Confirmed MOA via DrugBank API to resolve DG002
- Direct preclinical or clinical evidence of FGFR inhibition in pulmonary hypertension models
- Confirmation of Taiwan market-entry status before any further regulatory pathway assessment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.